Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 –blocking monoclonal antibody. From Wikipedia
New data presented at AACR highlights dostarlimab's potential to replace invasive treatments for cancers with specific genetic mutations.
